A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia.
Adolescent
Adult
Algorithms
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Clinical Decision-Making
Clinical Trials, Phase II as Topic
/ statistics & numerical data
Combined Modality Therapy
Datasets as Topic
Female
Hematopoietic Stem Cell Transplantation
/ standards
Humans
Leukemia, Myeloid, Acute
/ drug therapy
Male
Middle Aged
Models, Theoretical
Multicenter Studies as Topic
/ statistics & numerical data
Neoplasm, Residual
Nuclear Proteins
/ genetics
Nucleophosmin
Precision Medicine
Prognosis
Randomized Controlled Trials as Topic
/ statistics & numerical data
Remission Induction
Risk Assessment
Transplantation, Homologous
Young Adult
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
28 01 2021
28 01 2021
Historique:
received:
24
02
2020
accepted:
05
08
2020
pubmed:
2
9
2020
medline:
26
5
2021
entrez:
2
9
2020
Statut:
ppublish
Résumé
A multistage model instructed by a large dataset (knowledge bank [KB] algorithm) has recently been developed to improve outcome predictions and tailor therapeutic decisions, including hematopoietic stem cell transplantation (HSCT) in acute myeloid leukemia (AML). We assessed the performance of the KB in guiding HSCT decisions in first complete remission (CR1) in 656 AML patients younger than 60 years from the ALFA-0702 trial (NCT00932412). KB predictions of overall survival (OS) were superior to those of European LeukemiaNet (ELN) 2017 risk stratification (C-index, 68.9 vs 63.0). Among patients reaching CR1, HSCT in CR1, as a time-dependent covariate, was detrimental in those with favorable ELN 2017 risk and those with negative NPM1 minimal residual disease (MRD; interaction tests, P = .01 and P = .02, respectively). Using KB simulations of survival at 5 years in a scenario without HSCT in CR1 (KB score), we identified, in a similar time-dependent analysis, a significant interaction between KB score and HSCT, with HSCT in CR1 being detrimental only in patients with a good prognosis based on KB simulations (KB score ≥40; interaction test, P = .01). We could finally integrate ELN 2017, NPM1 MRD, and KB scores to sort 545 CR1 patients into 278 (51.0%) HSCT candidates and 267 (49.0%) chemotherapy-only candidates. In both time-dependent and 6-month landmark analyses, HSCT significantly improved OS in HSCT candidates, whereas it significantly shortened OS in chemotherapy-only candidates. Integrating KB predictions with ELN 2017 and MRD may thus represent a promising approach to optimize HSCT timing in younger AML patients.
Identifiants
pubmed: 32871585
pii: S0006-4971(21)00151-8
doi: 10.1182/blood.2020005524
doi:
Substances chimiques
NPM1 protein, human
0
Nuclear Proteins
0
Nucleophosmin
117896-08-9
Banques de données
ClinicalTrials.gov
['NCT00932412']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
524-532Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 by The American Society of Hematology.